IP Library › Granted Patent US 12,304,943
Granted Patent B2
US 12,304,943 · App. 18/807,825 · Granted May 20, 2025

April and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Inventors: Stacey Dillon (Seattle, WA); Mark Rixon (Seattle, WA); Lawrence Evans (Seattle, CA); Daniel William Demonte (Seattle, WA); Joseph L. Kuijper (Seattle, WA); Stanford L. Peng (Seattle, WA)
Assignee: Alpine Immune Sciences, Inc.
C07K14/70578A61K38/1774A61K38/1793A61K47/6425A61P37/06C07K14/7151A61K38/00A61K2039/505C07K2317/76C07K2317/92C07K2319/30C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,304,943
App. No.
18/807,825
Granted
May 20, 2025
Kind
B2
Abstract

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunomodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

Claims (5)

1. A variant TACI-Fc fusion protein as set forth as the amino acid sequence in SEQ ID NO: 167.

2. A pharmaceutical composition comprising the variant TACI-Fc fusion protein of claim 1 and a pharmaceutically acceptable excipient.

3. A variant TACI-Fc fusion protein that is a homodimer comprising two identical copies of the variant TACI-Fc fusion protein, wherein each polypeptide of the homodimer is set forth as the amino acid sequence in SEQ ID NO: 167 linked by a covalent disulfide bond.

4. A pharmaceutical composition comprising the homodimer of claim 3 and a pharmaceutically acceptable excipient.

5. A pharmaceutical composition comprising a variant TACI-Fc fusion protein homodimer and a pharmaceutically acceptable excipient, wherein each polypeptide of the homodimer is set forth as the amino acid sequence in SEQ ID NO. 167.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2025
From: DILLON, STACEY; RIXON, MARK; EVANS, LAWRENCE; DEMONTE, DANIEL WILLIAM; KUIJPER, JOSEPH L.; PENG, STANFORD L.
To: ALPINE IMMUNE SCIENCES, INC.
Reel/Frame 070311/0383 →
Continuity (5)
Continuation 17315168 · May 7, 2021
Provisional Application 63080643 · Sep 18, 2020
Provisional Application 63034361 · Jun 3, 2020
Provisional Application 63022373 · May 8, 2020
Related Publication 20240400643A1 · Dec 5, 2024
References Cited (400)
US 5168062A · Stinski · 1992 [cited by applicant]
US 5283173A · Fields et al. · 1994 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5443964A · Pickup et al. · 1995 [cited by applicant]
US 5457035A · Baum et al. · 1995 [cited by applicant]
US 5468614A · Fields et al. · 1995 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5698530A · Schlom et al. · 1997 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5969102A · Bram et al. · 1999 [cited by applicant]
US 6143290A · Zhang et al. · 2000 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6596535B1 · Carter · 2003 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6855317B2 · Koelle et al. · 2005 [cited by applicant]
US 6936257B1 · Bennett · 2005 [cited by applicant]
US 6998252B1 · Moss et al. · 2006 [cited by applicant]
US 7125717B2 · Carter · 2006 [cited by applicant]
US 7138501B2 · Ruben et al. · 2006 [cited by applicant]
US 7220840B2 · Ruben et al. · 2007 [cited by applicant]
US 7247615B2 · Schlom et al. · 2007 [cited by applicant]
US 7332581B2 · Presta · 2008 [cited by applicant]
US 7368116B2 · Schlom et al. · 2008 [cited by applicant]
US 7371826B2 · Presta · 2008 [cited by applicant]
US 7378087B2 · Jefferies et al. · 2008 [cited by applicant]
US 7501497B2 · Rixon et al. · 2009 [cited by applicant]
US 7550296B2 · Hermiston et al. · 2009 [cited by applicant]
US 7605236B2 · Ruben et al. · 2009 [cited by applicant]
US 7635767B2 · Rixon et al. · 2009 [cited by applicant]
US 7833529B1 · Gross et al. · 2010 [cited by applicant]
US 7850967B2 · Kalled et al. · 2010 [cited by applicant]
US 7862814B2 · Rixon et al. · 2011 [cited by applicant]
US 7879328B2 · Ruben et al. · 2011 [cited by applicant]
US 7951919B2 · Rixon et al. · 2011 [cited by applicant]
US 7964711B2 · Rixon et al. · 2011 [cited by applicant]
US 8101181B2 · Ruben et al. · 2012 [cited by applicant]
US 8193316B2 · Fang et al. · 2012 [cited by applicant]
US 8202698B2 · Hsu et al. · 2012 [cited by applicant]
US 8524232B2 · Rixon et al. · 2013 [cited by applicant]
US 8637021B2 · Del Rio et al. · 2014 [cited by applicant]
US 8669350B2 · Chou et al. · 2014 [cited by applicant]
US 8815238B2 · Rixon et al. · 2014 [cited by applicant]
US 8852591B2 · Ponce et al. · 2014 [cited by applicant]
US 8911726B2 · Takahashi et al. · 2014 [cited by applicant]
US 8956611B2 · Ponce et al. · 2015 [cited by applicant]
US 9168286B2 · Chevrier et al. · 2015 [cited by applicant]
US 9187548B2 · Ruben et al. · 2015 [cited by applicant]
US 9290582B2 · Yang et al. · 2016 [cited by applicant]
US 9346878B2 · Rixon et al. · 2016 [cited by applicant]
US 9545086B2 · MacKay et al. · 2017 [cited by applicant]
US 9969808B2 · Van Eenennaam et al. · 2018 [cited by applicant]
US 10183967B2 · Blum et al. · 2019 [cited by applicant]
US 10377830B2 · Van Eenennaam et al. · 2019 [cited by applicant]
US 10385123B2 · Myette et al. · 2019 [cited by applicant]
US 10562954B2 · Cai et al. · 2020 [cited by applicant]
US 10954296B2 · Myette et al. · 2021 [cited by applicant]
US 10961316B2 · Van Eenennaam et al. · 2021 [cited by applicant]
US 10968270B2 · Myette et al. · 2021 [cited by applicant]
US 11136385B2 · Myette et al. · 2021 [cited by applicant]
US 11274140B2 · Dillon et al. · 2022 [cited by applicant]
US 11698369B2 · Berenson · 2023 [cited by applicant]
US 20030059937A1 · Ruben et al. · 2003 [cited by applicant]
US 20030103986A1 · Rixon et al. · 2003 [cited by applicant]
US 20030223996A1 · Ruben et al. · 2003 [cited by applicant]
US 20040013674A1 · Ambrose et al. · 2004 [cited by applicant]
US 20050014934A1 · Hinton et al. · 2005 [cited by applicant]
US 20050163775A1 · Chan et al. · 2005 [cited by applicant]
US 20060024298A1 · Lazar et al. · 2006 [cited by applicant]
US 20060067933A1 · Gross et al. · 2006 [cited by applicant]
US 20060286093A1 · Gross et al. · 2006 [cited by applicant]
US 20070086979A1 · Chevrier et al. · 2007 [cited by applicant]
US 20080181886A1 · Kelley · 2008 [cited by applicant]
US 20090148462A1 · Chevrier et al. · 2009 [cited by applicant]
US 20090186040A1 · Busby et al. · 2009 [cited by applicant]
US 20090226440A1 · Grey · 2009 [cited by applicant]
US 20090291080A1 · Gottenberg et al. · 2009 [cited by applicant]
US 20100111953A1 · Ruben et al. · 2010 [cited by applicant]
US 20100239580A1 · Del Rio et al. · 2010 [cited by applicant]
US 20100256337A1 · Eon-Duval · 2010 [cited by applicant]
US 20100261887A1 · Del Rio et al. · 2010 [cited by applicant]
US 20100297122A1 · Del Rio et al. · 2010 [cited by applicant]
US 20110014190A1 · Migone et al. · 2011 [cited by applicant]
US 20110110950A1 · Kalled et al. · 2011 [cited by applicant]
US 20110117093A1 · Ruben et al. · 2011 [cited by applicant]
US 20110293610A1 · Ruben et al. · 2011 [cited by applicant]
US 20110311548A1 · Wasserman et al. · 2011 [cited by applicant]
US 20150322158A1 · Migone et al. · 2015 [cited by applicant]
US 20160017041A1 · Violette et al. · 2016 [cited by applicant]
US 20160311914A1 · Migone et al. · 2016 [cited by applicant]
US 20170081387A1 · Cai et al. · 2017 [cited by applicant]
US 20170145086A1 · Myette et al. · 2017 [cited by applicant]
US 20190241633A1 · Fotin_Mleczek et al. · 2019 [cited by applicant]
US 20190330326A1 · Myette et al. · 2019 [cited by applicant]
US 20200326339A1 · Berenson · 2020 [cited by applicant]
US 20210087253A1 · Fang et al. · 2021 [cited by applicant]
US 20210221900A1 · Van Eenennaam et al. · 2021 [cited by applicant]
US 20210238295A1 · Meher · 2021 [cited by applicant]
US 20210388054A1 · Dillon et al. · 2021 [cited by applicant]
US 20220002381A1 · Fang et al. · 2022 [cited by applicant]
US 20220133633A1 · Xu et al. · 2022 [cited by applicant]
US 20220235124A1 · Myette et al. · 2022 [cited by applicant]
US 20230210948A1 · Wax et al. · 2023 [cited by applicant]
US 20230241168A1 · Dillon et al. · 2023 [cited by applicant]
US 20240002468A1 · Fang et al. · 2024 [cited by applicant]
US 20240018212A1 · Fang et al. · 2024 [cited by applicant]
US 20240218045A1 · Dillon et al. · 2024 [cited by applicant]
US 20240279310A1 · Dillon et al. · 2024 [cited by applicant]
CA 2446734A1 · 2002 [cited by applicant]
CA 2453995A1 · 2003 [cited by applicant]
CA 2492447A1 · 2004 [cited by applicant]
CA 2501459A1 · 2004 [cited by applicant]
CA 2585927A1 · 2006 [cited by applicant]
CA 2661872A1 · 2008 [cited by applicant]
CA 2674213A1 · 2008 [cited by applicant]
CA 2690119A1 · 2008 [cited by applicant]
CA 2701221A1 · 2009 [cited by applicant]
CA 2703545A1 · 2009 [cited by applicant]
CA 2705357C · 2009 [cited by applicant]
CA 2705435A1 · 2009 [cited by applicant]
CA 2763439A1 · 2010 [cited by applicant]
CA 2681728C · 2015 [cited by applicant]
CA 2661748C · 2016 [cited by applicant]
CA 2701329C · 2017 [cited by applicant]
CA 3019199A1 · 2017 [cited by applicant]
CA 3032120A1 · 2018 [cited by applicant]
CA 3040296A1 · 2018 [cited by applicant]
CA 3053804A1 · 2018 [cited by applicant]
CA 3053812A1 · 2018 [cited by applicant]
CA 3054068A1 · 2018 [cited by applicant]
CA 3070468A1 · 2019 [cited by applicant]
CA 3077509A1 · 2019 [cited by applicant]
CA 3078517A1 · 2019 [cited by applicant]
CA 3087149A1 · 2019 [cited by applicant]
CA 3091681A1 · 2019 [cited by applicant]
CA 3112578A1 · 2020 [cited by applicant]
CA 3117978A1 · 2020 [cited by applicant]
CN 102085368B · 2013 [cited by applicant]
EP 1746106 · 2007 [cited by applicant]
EP 2116259 · 2012 [cited by applicant]
EP 2431054 · 2012 [cited by applicant]
EP 2139517 · 2013 [cited by applicant]
EP 2161287 · 2015 [cited by applicant]
EP 3299378 · 2018 [cited by applicant]
EP 3415528 · 2018 [cited by applicant]
JP 2003533218A · 2003 [cited by applicant]
JP 2004533997A · 2004 [cited by applicant]
JP 2006517191A · 2006 [cited by applicant]
JP 2007526220A · 2007 [cited by applicant]
JP 2009504668A · 2009 [cited by applicant]
JP 2009507777A · 2009 [cited by applicant]
JP 2009537563A · 2009 [cited by applicant]
JP 2010501622 · 2010 [cited by applicant]
JP 2011523037 · 2011 [cited by applicant]
JP 2018518974A · 2018 [cited by applicant]
JP 2019521643 · 2019 [cited by applicant]
KR 20130118315A · 2013 [cited by applicant]
WO WO1993010151 · 1993 [cited by applicant]
WO WO1994029351 · 1994 [cited by applicant]
WO WO1998018921 · 1998 [cited by applicant]
WO WO1998050431 · 1998 [cited by applicant]
WO WO1999038955 · 1999 [cited by applicant]
WO WO1999051642 · 1999 [cited by applicant]
WO WO2000067034 · 2000 [cited by applicant]
WO WO2000040716 · 2000 [cited by applicant]
WO WO2000042072 · 2000 [cited by applicant]
WO WO2001030843 · 2001 [cited by applicant]
WO WO2001060397 · 2001 [cited by applicant]
WO WO2001081417 · 2001 [cited by applicant]
WO WO2001087979 · 2001 [cited by applicant]
WO WO2002000717 · 2002 [cited by applicant]
WO WO2002002641 · 2002 [cited by applicant]
WO WO2002066516 · 2002 [cited by applicant]
WO WO2002094852 · 2002 [cited by applicant]
WO WO2003055979 · 2003 [cited by applicant]
WO WO2004056312 · 2004 [cited by applicant]
WO WO2004060911 · 2004 [cited by applicant]
WO WO2005005462 · 2005 [cited by applicant]
WO WO2005063816 · 2005 [cited by applicant]
WO WO2005100402 · 2005 [cited by applicant]
WO WO2006019447 · 2006 [cited by applicant]
WO WO2006029879 · 2006 [cited by applicant]
WO WO2006073941 · 2006 [cited by applicant]
WO WO2007005874 · 2007 [cited by applicant]
WO WO2007019573 · 2007 [cited by applicant]
WO WO2007019575 · 2007 [cited by applicant]
WO WO2007029879 · 2007 [cited by applicant]
WO WO2007134326 · 2007 [cited by applicant]
WO WO2008011636 · 2008 [cited by applicant]
WO WO2008025747 · 2008 [cited by applicant]
WO WO2008092117 · 2008 [cited by applicant]
WO WO2008154814 · 2008 [cited by applicant]
WO WO2008155134 · 2008 [cited by applicant]
WO WO2008157369 · 2008 [cited by applicant]
WO WO2009029342 · 2009 [cited by applicant]
WO WO2009062916 · 2009 [cited by applicant]
WO WO2009062926 · 2009 [cited by applicant]
WO WO2009062960 · 2009 [cited by applicant]
WO WO2009076524 · 2009 [cited by applicant]
WO WO2009132058 · 2009 [cited by applicant]
WO WO2009134633 · 2009 [cited by applicant]
WO WO2010003766 · 2010 [cited by applicant]
WO WO2010027827 · 2010 [cited by applicant]
WO WO2010027828 · 2010 [cited by applicant]
WO WO2010077634 · 2010 [cited by applicant]
WO WO2010093993 · 2010 [cited by applicant]
WO WO2011109280 · 2011 [cited by applicant]
WO WO2012032112 · 2012 [cited by applicant]
WO WO2012125850 · 2012 [cited by applicant]
WO WO2012141984 · 2012 [cited by applicant]
WO WO2012149364 · 2012 [cited by applicant]
WO WO2013041029 · 2013 [cited by applicant]
WO WO2013130683 · 2013 [cited by applicant]
WO WO2013149167 · 2013 [cited by applicant]
WO WO2013184912 · 2013 [cited by applicant]
WO WO2015107026 · 2015 [cited by applicant]
WO WO2015181343 · 2015 [cited by applicant]
WO WO2016011083 · 2016 [cited by applicant]
WO WO2016023001 · 2016 [cited by applicant]
WO WO2016210293 · 2016 [cited by applicant]
WO WO2017011804 · 2017 [cited by applicant]
WO WO2017019846 · 2017 [cited by applicant]
WO WO2017091683 · 2017 [cited by applicant]
WO WO2017106061 · 2017 [cited by applicant]
WO WO2017181152 · 2017 [cited by applicant]
WO WO2017222593 · 2017 [cited by applicant]
WO WO2018022945 · 2018 [cited by applicant]
WO WO2018236995 · 2018 [cited by applicant]
WO WO2019074983 · 2019 [cited by applicant]
WO WO2019110209 · 2019 [cited by applicant]
WO WO2019136179 · 2019 [cited by applicant]
WO WO2019223581 · 2019 [cited by applicant]
WO WO2019241758 · 2019 [cited by applicant]
WO WO2020028572 · 2020 [cited by applicant]
WO WO2020047329 · 2020 [cited by applicant]
WO WO2020113141 · 2020 [cited by applicant]
WO WO2020214867 · 2020 [cited by applicant]
WO WO2020252421 · 2020 [cited by applicant]
WO WO2021049606 · 2021 [cited by applicant]
WO WO2021115321 · 2021 [cited by applicant]
WO WO2021128027 · 2021 [cited by applicant]
WO WO2021226551 · 2021 [cited by applicant]
WO WO2021226553 · 2021 [cited by applicant]
WO WO2022236335 · 2022 [cited by applicant]
WO WO2023236967 · 2023 [cited by applicant]
WO WO2024077018 · 2024 [cited by applicant]
Abdel-Hamid et al., “B cell activating factor gene polymorphisms in patients with risk of idiopathic thrombocytopenia purpura,” Am J Med Sci. Jul. 2011;342(1):9-14. [cited by applicant]
Alperovich et al., “New immunosuppresor strategies in the treatment of murine lupus nephritis,” Lupus. (2007) 16(1): 18-24. [cited by applicant]
Andrews et al., “Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains,” J Exp Med. (1978) 148(5): 1198-1215. [cited by applicant]
Ansell et al., “Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma,” Clin Cancer Res. (2008) 14(4): 1105-1110. [cited by applicant]
Anthera Pharmaceuticals Inc, Form 10-K, Annual Report, Filed Mar. 5, 2018, 168 pages. [cited by applicant]
Anthera, “Anthera Announces Top LineFinal Data from the ExtensionPeriod of the Phase 2 BRIGHT-SC Study of Blisibimod inPatients with IgA Nephropathy,” Press Release Aug. 28, 2017, 7 pages. [cited by applicant]
Asashima et al., “Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris,” Br J Dermatol. (2006) 155(2):330-6. [cited by applicant]
Bachmann et al., “The EVH2 Domain of the Vasodilator-stimulated Phosphoprotein Mediates Tetramerization, F-actin Binding, and Actin Bundle Formation,” J Biol Chem. (1999) 274(33):23549-23557. [cited by applicant]
Baert et al., “The role of APRIL—A proliferation inducing ligand—In autoimmune diseases and expectations from its targeting,” J Autoimmun (2018) 95:179-190. [cited by applicant]
Bagchi et al., “Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study,” Kidney Int Rep (2021) 6(6):1661-1668. [cited by applicant]
Bag-Ozbek et al., “Emerging B-Cell Therapies in Systemic Lupus Erythematosus,” Ther Clin Risk Manag (2021) 17:39-54. [cited by applicant]
Banchereau et al., “Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients,” Cell (2016) 165(6):1548-1550. [cited by applicant]
Barrett et al., “Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy,” Nephrol Dial Transplant (2020) 35(4):599-606. [cited by applicant]
Baumgartner et al., “The role of the WSXWS equivalent motif in growth hormone receptor function,” J Biol Chem. (1994) 269(46): 29094-101. [cited by applicant]
Benatuil et al., “An improved yeast transformation method for the generation of very large human antibody libraries,” Protein Eng Des Sel. (2010) 23(4): 155-159. [cited by applicant]
Benoist et al., “In vivo sequence requirements of the SV40 early promotor region,” Nature. (1981) 290(5804): 304-10. [cited by applicant]
Benson et al., “Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL,” J Immunol. (2008) 180(6): 3655-3659. [cited by applicant]
Bilsborough et al., “TACI-Ig prevents the development of airway hyperresponsiveness in a murine model of asthma,” Clin Exp Allergy. (2008) 38(12): 1959-1968. [cited by applicant]
Blair et al., “Belimumab: A Review in Systemic Lupus Erythematosus,” Drugs (2018) 78(3):355-366. [cited by applicant]
Bossen et al, “BAFF, APRIL and their receptors: structure, function and signaling,” Semin Immunol. (2006) 18(5): 263-275. [cited by applicant]
Brown et al., “Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesis,” J Virol. (1999) 73(11):9011-9020. [cited by applicant]
Bruggemann et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies,” J Exp Med. (1987) 166(5):1351-1361. [cited by applicant]
Buchschacher et al., “Human immunodeficiency virus vectors for inducible expression of foreign genes,” J Virol. (1992) 66(5):2731-2739. [cited by applicant]
Busch et al., “Dimers, leucine zippers and DNA-binding domains,” Trends Genet. (1990) 6(2): 36-40. [cited by applicant]
Carbonatto et al., “Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept,” Toxicol Sci. (2008) 105(1): 200-210. [cited by applicant]
Cavallaro et al., “Antibody based therapeutics for autoimmune hemolytic anemia,” Expert Opin Biol Ther. (2023) 23(12):1227-1237. [cited by applicant]
CAS Reg. No. 2490217428_1, (Oct. 12, 2020), 3 pages. [cited by applicant]
Chen et al., “Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis,” Clin Pharmacokinet. (2014) 53(11): 1033-44. [cited by applicant]
Chen et al., “Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis,” Br J Clin Pharmacol. (2016) 82(1): 41-52. [cited by applicant]
Chen et al., “Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy,” Clin J Am Soc Nephrol (2019) 14(10):1458-1465. [cited by applicant]
Chiche et al., “Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures,” Arthritis Rheumatol (2014) 66(6):1583-95. [cited by applicant]
Christadoss et al., “Immunotherapy for myasthenia gravis: a murine model,” J Immunol. (1986) 136(7):2437-40. [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci U S A. (1998) 95(2):652-656. [cited by applicant]
Consonni et al., “A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146,” Front Immunol (2017) 8:1133, 12 pages. [cited by applicant]
Cooper et al., “Immune Thrombocytopenia,” N Engl J Med (2019) 381(10):945-955. [cited by applicant]
Cornetta et al., “No. retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus,” Hum Gene Ther. (1991) Fall;2(3):215-9. [cited by applicant]
Couser, “Primary Membranous Nephropathy,” Clin J Am Soc Nephrol (2017) 12(6):983-997. [cited by applicant]
Cragg et al., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,” Blood. (2004) 103(7):2738-2743. [cited by applicant]
Cragg et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,” Blood. (2003) 101(3):1045-1052. [cited by applicant]
Daikh et al., “Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways,” J Immunol. (1997) 159(7): 3104-8. [cited by applicant]
Dall'Era et al., “Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus,” Arthritis Rheum. (2007) 56(12): 4142-4150. [cited by applicant]
De Marchi et al., “Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus,” Clin Exp Rheumatol (2017) 35(6):1056. [cited by applicant]
De Wet et al., “Firefly luciferase gene: structure and expression in mammalian cells,” Mol Cell Biol. (1987) 7(2): 725-37. [cited by applicant]
Deisenhofer et al., “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from [cited by applicant]
Deng et al., “Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: Correlation with clinical outcome,” J Neuroimmunol (2017) 305:84-91. [cited by applicant]
Desmarets et al., “Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model,” Blood (2009) 114(11):2315-22. [cited by applicant]
Dillon et al. “ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases,” Abstract OP… [cited by applicant]
Dillon et al., “B Cell Modulatory Variant TNF Receptor Domains (vTDs) Identified by Directed Evolution to Inhibit BAFF and APRIL, Alone or Combined with Variant Ig Domains (vlgD™) that Inhibit T Cell Costimulation, for … [cited by applicant]
Dillon et al., “B Cell Modulatory Variant TNF Receptor Domains (vTDs) Identified by Directed Evolution to Inhibit BAFF and APRIL, Alone or Combined with Variant Ig Domains (vlgD™) that Inhibit T Cell Costimulation, for … [cited by applicant]
Dillon et al., “B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglo… [cited by applicant]
Ding et al., “Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from the amino-terminal domain of the GluN1 subunit,” J Neuroinflammation (2021) 18(1):53, 10 pages. [cited by applicant]
Ding et al., “Telitacicept Following Plasma Exchange in the Treatment of Subjects with Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study,” Front Neurol. (2021) 12: 596791. [cited by applicant]
Duncan et al., “The binding site for C1q on IgG,” Nature. Apr. 21, 1988;332(6166):738- 40. [cited by applicant]
Emmerich et al., “High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenia purpura,” Br J Haematol (2007) 136(2):309-14. [cited by applicant]
Engelman et al., “Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication,” J Virol. 1995 69(5):2729-2736. [cited by applicant]
Eslami et al., “Function, occurrence and inhibition of different forms of BAFF,” Curr Opin Immunol. (2021) 71: 75-80. [cited by applicant]
European Communication pursuant to Article 94(3) EPC, mailed on Jul. 17, 2024, for European Patent Application No. 21730003.7 filed on May 7, 2021, 7 pages. [cited by applicant]
FDA, Bioanalytical Method Validation Guidance for Industry (May 2018), 44 pages. Retrieved from: https://www.fda.gov/media/70858/download. [cited by applicant]
Feng et al., “High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia,” J Thromb Haemost (2017) 15(9):1845-1858. [cited by applicant]
Floege et al., “Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference,” Kidney Int (2019) 95(2):268-280. [cited by applicant]
Foecking et al., “Powerful and versatile enhancer-promoter unit for mammalian expression vectors,” Gene. (1986) 45(1): 101-105. [cited by applicant]
Francis et al., “Membranous Nephropathy: A Journey From Bench to Bedside,” Am J Kidney Dis (2016) 68(1):138-47. [cited by applicant]
Furie et al., “A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus,” Arthritis Rheum. (2011) 63(12):… [cited by applicant]
Furie et al., “Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis,” N Engl J Med (2020) 383(12):1117-1128. [cited by applicant]
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” J Immunol Methods. Mar. 28, 1997;202(2):163-71. [cited by applicant]
Genovese et al., “Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial,” Arthr… [cited by applicant]
Gentz et al., “Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains,” Science. (1989) 243(4899): 1695-1699. [cited by applicant]
Gherardi et al., “Recombinant poxviruses as mucosal vaccine vectors,” J Gen Virol. (2005) 86(Pt 11):2925-2936. [cited by applicant]
Ginzler et al., “Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial,” Arthritis Res Ther. (2012) 14(1): R33. [cited by applicant]
Glabinski et al., “Murine experimental autoimmune encephalomyelitis: a model of immune-mediated inflammation and multiple sclerosis,” Methods Enzymol. (1997) 288: 182-190. [cited by applicant]
Gonzalez-Mendioroz et al., “Structural analysis of the inhibition of APRIL by TACI and BCMA through molecular dynamics simulations,” J Mol Graph Model. (2013) 39:13-22. [cited by applicant]
Gordon et al., “Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL,” Arthritis Rheumatol. (2017) 69(1): 122-130. [cited by applicant]
Gorman et al., “The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection,” Proc Natl Acad Sci U S A. (1982) 79(22): 6777-6781. [cited by applicant]
Gross et al., “TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease,” Nature. (2000) 404(6781): 995-999. [cited by applicant]
Gross et al., “TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS,” Immunity. (2001) 15(2): 289-302. [cited by applicant]
Gu et al., “Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications,” Autoimmunity (2009) 42(8):692-8. [cited by applicant]
Guerra et al., “Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells,” J Virol. (2006) 80(2): 985-98. [cited by applicant]
Hahne et al., “APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth,” J Exp Med. (1998) 188(6): 1185-90. [cited by applicant]
Hamer et al., “Regulation in vivo of a cloned mammalian gene: cadmium induces the transcription of a mouse metallothionein gene in SV40 vectors,” J Mol Appl Genet. (1982) 1(4): 273-288. [cited by applicant]
Haselmayer et al., “A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells,” Eur J Immunol. (2017) 47(6): 1075-1085. [cited by applicant]
Hebert et al., “Rituximab in pemphigus,” Immunotherapy (2018) 10(1):27-37. [cited by applicant]
Hellstrom et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas,” Proc Natl Acad Sci U S A. (1986) 83(18):7059-7063. [cited by applicant]
Hellstrom et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside,” Proc Natl Acad Sci U S A. (1985) 82(5):1499-1502. [cited by applicant]
Hu et al., “Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy,” J Virol. (2001) 75(21):10300-10308. [cited by applicant]
Huard et al., “Selective APRIL blockade delays systemic lupus erythematosus in mouse,” PLoS One. (2012) 7(2): e31837. [cited by applicant]
Hymowitz et al., “Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding,” J Biol Chem. (2005) 280(8): 7218-7227. [cited by applicant]
Idusogie et al., “Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc,” J Immunol. (2000) 164(8):4178-4184. [cited by applicant]
Isenberg et al., “Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial),” Ann Rheum Dis. (2015) 74(11… [cited by applicant]
Jacob et al., “Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice,” Arthritis Rheum (2012) 64(5):1610-9. [cited by applicant]
Jager et al., “Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting,” Blood Rev (2019) 100648, 66 pages. [cited by applicant]
Johann et al., “GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus,” J Virol. (1992) 66(3):1635-1640. [cited by applicant]
Kabat et al., “Sequences of Proteins of Immunological Interest,” Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991), 83 pages. [cited by applicant]
Kaegi et al., “Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders,” Front Immunol. (2020) 11:433. [cited by applicant]
Kappos et al., “Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial,” Lancet Neurol. (2014) 13(4): 353-63. [cited by applicant]
Kaufman et al., “Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus,” Nucleic Acids Res. (1991) 19(16): 4485-4490. [cited by applicant]
Kelkka et al., “Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature,” Antioxid Redox Signal. (2014) 21(16): 2231-2245. [cited by applicant]
Kelly et al., “APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death” Cancer Res. (2000) 60(4): 1021-1027. [cited by applicant]
Khodadadi et al., “The Maintenance of Memory Plasma Cells,” Front Immunol (2019) 10:721, 17 pages. [cited by applicant]
Kimberley et al., “The design and characterization of receptor-selective APRIL variants,” J Biol Chem. (2012) 287(44): 37434-37446. [cited by applicant]
Klarquist et al., “The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice,” J Vis Exp. (2015) (105): e53319. [cited by applicant]
Koenen et al., “A novel bispecific antihuman CD40/CD86 fusion protein with T-cell tolerizing potential,” Transplantation (2004) 78(10):1429-1438. [cited by applicant]
Kofler et al., “Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia,” Leukemia. (2012) 26(4): 841-844. [cited by applicant]
Kolberg, “Gene-transfer virus contaminant linked to monkey's cancer,” J NIH Res. (1992) 4:43-44. [cited by applicant]
Krumbholz et al., “B cells and antibodies in multiple sclerosis pathogenesis and therapy,” Nat Rev Neurol (2012) 8(11):613-23. [cited by applicant]
Labrijn et al., “Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo,” Nat Biotechnol. Aug. 27, 2009(8):767-71. [cited by applicant]
Larsen et al., “Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties,” Am J Transplant. Mar. 2005;5(3):443-53. [cited by applicant]
Lazar-Molnar et al., “Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2,” Proc Natl Acad Sci U S A (2008) 105(30):10483-8. [cited by applicant]
Lenert et al., “Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents,” Drug Des Devel Ther (2015) 9:333-47. [cited by applicant]
Levin, S.D., et al., “Novel Immunomodulatory proteins generated via directed evolution of variant IgSF domains.” Front Immunol., (2020) 10:3086, 17 pages. [cited by applicant]
Lindstrom et al., “Production and Assay of Antibodies to Acetylcholine Receptors,” Methods Enzymol. (1981) ;74 Pt C:432-60. [cited by applicant]
Linsley et al., “Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors,” Immunity. (1994) 1(9): 793-801. [cited by applicant]
Liu et al., “BAFF inhibition: a new class of drugs for the treatment of autoimmunity,” Exp Cell Res (2011) 317(9):1270-7. [cited by applicant]
Liu et al., “Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner,” Arthritis Rheumatol. (2011) 63(1):219-29. [cited by applicant]
Lo et al., “Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers,” Kidney Week Abstract PO1843 (JASN 31: 2020), 11 pages. [cited by applicant]
Manzi et al., “Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III tri… [cited by applicant]
Marin-Rosales et al., “High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF 13B gene,” Clin Exp Med (2019) 19(2):183-190, 8 pages. … [cited by applicant]
Mayr et al., “Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA,” Infection. (1975);3:6-14. (English translation of abstract provided). [cited by applicant]
Mcknight et al., “Functional relationships between transcriptional control signals of the thymidine kinase gene of herpes simplex virus,” Cell. (1982) 31(2): 355-365. [cited by applicant]
Mcwilliams et al., “Mutations in the 5′ end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer,” J Virol. (2003) 77(20):11150-11157. [cited by applicant]
Merchant et al., “An efficient route to human bispecific IgG,” Nat Biotechnol. (1998) 16(7): 677-681. [cited by applicant]
Mercier et al., “A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1,” Proc Natl Acad Sci U S A. (2004) 101(16): 6188-6193. [cited by applicant]
Merrill et al., “Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study,” … [cited by applicant]
Merrill, J., Clinical Trials Report, “Biomarkers Relevant to Atacicept Effects in Systemic Lupus Erythrematosus Patients” Current Rheumatology Reports; 264. [cited by applicant]
Miller et al., “Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus,” J Virol. (1991) 65(5):2220-2224. [cited by applicant]
Miller et al., “Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection,” Mol Cell Biol. (1990) 10(8):4239-4242. [cited by applicant]
Miller, “Protein-protein recognition and the association of immunoglobulin constant domains,” J Mol Biol. Dec. 20, 1990;216(4):965-73. [cited by applicant]
Miyoshi et al. “Development of a self-inactivating lentivirus vector,” J Virol. (1998) 72(10):8150-8157. [cited by applicant]
Mizerska-Wasiak et al., “Relationship between serum IgA/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy,” Pediatr Nephrol. (2015) 30(7):1113-20, 8 pages. [cited by applicant]
Mohan et al., “Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis,” J Immunol. (1995) 154(3): 1470-1480. [cited by applicant]
Molin et al., “Two novel adenovi+A368rus vector systems permitting regulated protein expression in gene transfer experiments,” J Virol. (1998) 72(10):8358-8361. [cited by applicant]
Moore et al., “BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator,” Science. (1999) 285(5425): 260-263. [cited by applicant]
Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” J Immunol Methods. (1983) 65(1-2): 55-63. [cited by applicant]
Mujtaba et al., “IFN-t Suppresses Both the Autoreactive Humoral and Cellular Immune Responses and Induces Stable Remission in Mice with Chronic Experimental Allergic Encephalomyelitis,” Cell Immunol. (1998) 186(2): 94-1… [cited by applicant]
Mukhopadhyay et al., “Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase,” J Biol Chem. (1999) 274(23): 15978-1… [cited by applicant]
Munafo et al., “Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers,” Eur J Clin Pharmacol. (2007) 63(7): 647-656. [cited by applicant]
Myers et al., “Collagen-induced arthritis, an animal model of autoimmunity,” Life Sci. (1997) 61(19): 1861-1878. [cited by applicant]
Narumi et al., “Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo,” Am J Respir Cell Mol Biol. (1998) 19(6):936-941. [cited by applicant]
Navarra et al., “Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial,” Lancet. (2011) 377(9767): 721-731. [cited by applicant]
Nestorov et al., “Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis,” J Clin Pharmacol. (2008) 48(4): 406-417. [cited by applicant]
Nestorov et al., “Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus,” J Pharm Sci. (2010) 99(1): 524-538. [cited by applicant]
Netti et al., “Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy,” J Immunol Res (2019) 2019:8483650, 12 pages. [cited by applicant]
Neunert et al., “American Society of Hematology 2019 guidelines for immune thrombocytopenia,” Blood Adv. (2019) 3(23):3829-3866. [cited by applicant]
Nightingale et al., “Transient gene expression by nonintegrating lentiviral vectors,” Mol Ther. (2006) 13(6):1121-1132. [cited by applicant]
Partial European Search Report for Application No. 18793148.0, mailed Mar. 16, 2023, 3 pages. [cited by applicant]
Pena-Rossi et al., “An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus,” Lupus. (200… [cited by applicant]
Peng et al., “A long-acting PAI-1 inhibitor reduces thrombus formation,” Thromb Haemost (2017) 117(7):1338-1347. [cited by applicant]
Perez-Melgosa et al., “Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens,” J Immunol. (1999) 163(3): 1123-1127. [cited by applicant]
Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Int Immunol. (2006) 18(12):1759-1769. [cited by applicant]
Pfeifer et al., “Gene therapy: promises and problems,” Annu Rev Genomics Hum Genet. (2001);2:177-211. [cited by applicant]
Philpott et al., “Use of nonintegrating lentiviral vectors for gene therapy,” Hum Gene Ther. (2007) 18(6): 483-9. [cited by applicant]
Ponce, “Preclinical support for combination therapy in the treatment of autoimmunity with atacicept,” Toxicol Pathol. (2009) 37(1): 89-99. [cited by applicant]